<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Alkermes Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/alkermes-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ALKS) Risk-Reward Balanced at Alkermes</title>
		<link>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426</link>
		<comments>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426#comments</comments>
		<pubDate>Wed, 07 Mar 2012 17:19:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94426</guid>
		<description><![CDATA[We are maintaining a Neutral rating on Alkermes (ALKS) with a target price of $18.00. Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results.  This was the first full quarter for Alkermes plc, formed in September 2011, following the merger of Waltham, Massachusetts based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of  Elan Corporation (ELN). The merger has expanded the portfolio significantly resulting in a 185.7% increase in revenues during the quarter. The expanded portfolio caused management to increase the 2012 revenue projection. Revenues are projected in the range of $370-$400 million, up from the previous guidance of $350-$380 million. Given the expanded product portfolio, we expect the company to achieve/beat the increased guidance. Consequently, the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Posts Lower Loss</title>
		<link>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689</link>
		<comments>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689#comments</comments>
		<pubDate>Tue, 25 Oct 2011 17:38:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[iShares S&P Target Date 2010]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NICE Systems Limited]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TZD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85689</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher revenues and lower expenses led to the lower year-over-year loss. Third quarter revenues, which included a $15 million milestone payment, increased 12.1% to $175 million. Revenues exceeded the Zacks Consensus Estimate of $166 million. Quarterly Details Quarterly revenues consisted of $155.1 million in product sales (up 0.7%) and $19.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Collaborative revenues included a $15 million milestone payment from Lilly on the launch of Bydureon in the EU. Collaborative ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387</link>
		<comments>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387#comments</comments>
		<pubDate>Thu, 01 Sep 2011 16:55:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82387</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. In August 2011, Alkermes disclosed financial results for the first quarter of fiscal 2012. Alkermes suffered a net loss (excluding special items but including stock-based compensation expense) of $0.04 per share which compared favorably with the year-ago loss of $0.14 per share. The Zacks Consensus Estimate was a loss of $0.11 per share. The narrower year-over-year loss was attributable to higher revenues recorded in the reported quarter. The lead product at Alkermes is Risperdal Consta for the treatment of schizophrenia and bipolar disorder. The drug is marketed worldwide by Johnson ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs</title>
		<link>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027</link>
		<comments>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:23:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80027</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. Second quarter revenues declined 3.8% to $158.1 million. Revenues, however, exceeded the Zacks Consensus Estimate of $156 million. Quarterly Details Total revenues for the quarter declined mainly due to lower net product sales. Quarterly revenues consisted of $154.8 million in product sales (down 4.8%) and $3.3 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $129 million in sales of Byetta (exenatide) and $25.8 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Presents Late Stage Degludec Data</title>
		<link>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249</link>
		<comments>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:06:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78249</guid>
		<description><![CDATA[Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low blood sugar) versus Sanofi Aventis’(SNY) Lantus in patients with type II diabetes. Novo Nordisk presented data from two, late stage, 52-week clinical trials, one in patients with type I and the other in victims of type II diabetes. These data were presented at the American Diabetes Association. Degludec particularly reduced nocturnal hypoglycemia (night-time episodes of excessively low blood sugar) versus Lantus in patients with type I or type II diabetes. Nocturnal hypoglycemia is highly feared by diabetics, and hence a reduced threat of it represents a real commercial edge for Degludec. Apart from the two studies, Novo Nordisk also presented data ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229</link>
		<comments>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:31:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78229</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32).  ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole).  Alkermes intends to present complete data from the study at an upcoming medical conference. The double-blind, randomized, placebo-controlled 20-week study evaluated the safety, tolerability and pharmacokinetics of ALKS 9070 (once-monthly) at 3 doses in patients suffering from chronic, stable schizophrenia. Data from the study revealed that the candidate was generally well tolerated at all  doses and achieved therapeutically relevant plasma concentrations of Abilify. The pharmacokinetic profile backed the once-monthly dosing of ALKS 9070. Encouraged by the positive results, the company intends to commence a pivotal development program for the candidate by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Presents Diabetes Study Data</title>
		<link>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767</link>
		<comments>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:42:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77767</guid>
		<description><![CDATA[Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human Glucagon-Like Peptide- 1 (GLP-1) analogue for the treatment of type II diabetes. The first study showed that treatment with Victoza (once daily) in combination with metformin and/or sulfonylurea caused more patients to achieve control over their blood sugar levels compared to those treated with other commonly used diabetes drugs like Merck’s (MRK) Januvia and Amylin Pharmaceuticals’ (AMLN) Byetta. Moreover, data also revealed that patients underwent significant weight loss on switching over to Victoza therapy from Januvia. Novo Nordisk also presented data from another late stage study which investigated the effect of adding Levemir to the existing treatment regimen of Victoza and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Evenly Poised</title>
		<link>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334</link>
		<comments>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77334</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. We are positive on Alkermes’ decision to buy  Elan Corporation’s (ELN) drug delivery unit. The deal is expected to boost Alkermes’ cash earnings immediately following its closure. The product portfolio at Alkermes will be strengthened following the merger. Alkermes currently has two marketed drugs namely Risperdal Consta and Vivitrol in its product portfolio. Risperdal Consta is marketed worldwide by Johnson &#38; Johnson (JNJ) for the treatment of schizophrenia and bipolar disorder. The drug is manufactured by Alkermes. The other approved product at Alkermes is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals, Partners Eli Lilly and Alkermes Learn Bydureon Gains EU Approval</title>
		<link>http://www.stockbloghub.com/2011/06/22/amln-amylin-pharmaceuticals-partners-eli-lilly-and-alkermes-learn-bydureon-gains-eu-approval/77181</link>
		<comments>http://www.stockbloghub.com/2011/06/22/amln-amylin-pharmaceuticals-partners-eli-lilly-and-alkermes-learn-bydureon-gains-eu-approval/77181#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:06:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77181</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received a boost with the European Commission granting marketing authorization to Bydureon (exenatide once-weekly) for the treatment of type II diabetes. Bydureon is the first once-weekly treatment to gain approval for type II diabetes. Approval was granted for use in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione. EU Approval Was Expected EU approval was expected as, earlier in April, Bydureon had received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). While anticipated, the final approval of Bydureon, nevertheless, comes as a relief for Amylin which has recently been at the receiving end of a series ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/amln-amylin-pharmaceuticals-partners-eli-lilly-and-alkermes-learn-bydureon-gains-eu-approval/77181/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Stock Market News for May 10, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/05/10/alks-stock-market-news-for-may-10-2011-market-news/73711</link>
		<comments>http://www.stockbloghub.com/2011/05/10/alks-stock-market-news-for-may-10-2011-market-news/73711#comments</comments>
		<pubDate>Tue, 10 May 2011 16:55:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[Baker Hughes Inc.]]></category>
		<category><![CDATA[BHI]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Dollar Thrifty Automotive Group Inc]]></category>
		<category><![CDATA[DTG]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[Frontier Oil Corporation]]></category>
		<category><![CDATA[FTO]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hertz Global Holdings Inc.]]></category>
		<category><![CDATA[HOC]]></category>
		<category><![CDATA[Holly Corporation]]></category>
		<category><![CDATA[HTZ]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[NVDA]]></category>
		<category><![CDATA[NVIDIA Corporation]]></category>
		<category><![CDATA[SGY]]></category>
		<category><![CDATA[Stone Energy Corporation]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73711</guid>
		<description><![CDATA[After suffering a slump last week, commodities made a strong comeback yesterday and lifted the benchmarks higher. Energy shares joined in on the uptrend as crude prices once again rose above $100 per barrel. Meanwhile fresh worries about Greece’s credit ratings partially limited gains. The Dow Jones Industrial Average (DJIA) rose 0.4% to close at 12,684.68. The Standard &#38; Poor 500 (S&#38;P 500) gained 0.5% and finished the day at 1,346.29. The Nasdaq Composite Index increased 0.6% to settle at 2,843.25. The fear-gauge CBOE Volatility Index dropped down to almost 17. On the New York Stock Exchange, composite volumes were low, at only 3 billion shares. For every couple of stocks that gained, one stock moved down. Markets witnessed a massive sell off of commodities last week as investors chose ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/alks-stock-market-news-for-may-10-2011-market-news/73711/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermesto Buy Elan Unit for $960 Million</title>
		<link>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637</link>
		<comments>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637#comments</comments>
		<pubDate>Mon, 09 May 2011 22:55:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[HBC]]></category>
		<category><![CDATA[HSBC HLDGS PLC ADS]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73637</guid>
		<description><![CDATA[Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately $960 million. The merged entity will be known as Alkermes plc and will be headquartered in Dublin, Ireland. The deal, expected to boost Alkermes’ cash earnings immediately following its closure, has been cleared by the board of directors of both companies. Morgan Stanley &#38; Co. (MS) and HSBC (HBC) have agreed to finance up to $450 million of the deal through term loans to Alkermes. Per the terms of the deal, Alkermes will make a cash payment of $500 million apart from giving Elan 31.9 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Reports Earnings Loss In-Line with Estimates</title>
		<link>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977</link>
		<comments>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977#comments</comments>
		<pubDate>Wed, 20 Apr 2011 21:35:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71977</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 24 cents per share in the first quarter of 2011, in line with the Zacks Consensus Estimate and 3 cents below the year-ago loss of 27 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. First quarter revenues declined 12.3% to $152.7 million. Revenues also missed the Zacks Consensus Estimate of $155 million. Quarterly Details Total revenues for the quarter declined 12.3% mainly due to lower net product sales. Quarterly revenues consisted of $150.8 million in product sales (down 12.5%) and $1.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $128 million in sales of Byetta (exenatide) and $22.8 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals, Eli Lilly, and Alkermes Get Positive Opinion for Bydureon</title>
		<link>http://www.stockbloghub.com/2011/04/18/amln-amylin-pharmaceuticals-eli-lilly-and-alkermes-get-positive-opinion-for-bydureon/71813</link>
		<comments>http://www.stockbloghub.com/2011/04/18/amln-amylin-pharmaceuticals-eli-lilly-and-alkermes-get-positive-opinion-for-bydureon/71813#comments</comments>
		<pubDate>Tue, 19 Apr 2011 03:32:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71813</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received good news regarding their pipeline candidate, Bydureon (exenatide once-weekly). Amylin, Eli Lilly and Alkermes said that Bydureon received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP issued an opinion in favor of approving Bydureon for the treatment of type II diabetes in combination with certain oral therapies. A final decision regarding the approvability of Bydureon should be delivered by the European Commission in 2-3 months. Approval would make Bydureon the first once-weekly type II diabetes treatment in the EU. The positive EU recommendation comes as a relief for Amylin which has recently been at the receiving end of a series of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/amln-amylin-pharmaceuticals-eli-lilly-and-alkermes-get-positive-opinion-for-bydureon/71813/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Company News for April 18, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/18/alks-company-news-for-april-18-2011-corporate-summary/71757</link>
		<comments>http://www.stockbloghub.com/2011/04/18/alks-company-news-for-april-18-2011-corporate-summary/71757#comments</comments>
		<pubDate>Mon, 18 Apr 2011 19:25:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BRNC]]></category>
		<category><![CDATA[Bronco Drilling Company Inc]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Finish Line Inc.]]></category>
		<category><![CDATA[FINL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[ROSE]]></category>
		<category><![CDATA[Rosetta Resources Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71757</guid>
		<description><![CDATA[• Chesapeake Energy Corp&#8217;s. (NYSE:CHK) share prices gained 0.25% after it announced plans to buy Bronco Drilling Co. (NASDAQ:BRNC) for $11 a share. The purchase price represents a 24% premium over Bronco’s average 90-day closing price • A report from Bloomberg cited that eBay Inc. (NASDAQ:EBAY) gains in its bid to grow its business in China • Share prices of French chip company Sequans Communications (NYSE:SQNS) fell 17.5% to close at $8.25 on its first day of trading on the New York Stock Exchange • Share prices of Bank of America (NYSE:BAC) fell 2.36% after the banking giant reported a 36% decline in first-quarter profits as the foreclosures crisis continued to squeeze its home loan business. Bank of America is the largest U.S. bank by assets • Shares of Merck (NYSE:MRK) rose 1.92% to $34.51 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/alks-company-news-for-april-18-2011-corporate-summary/71757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Analyst Reports Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/29/amln-amylin-pharmaceuticals-analyst-reports-neutral-on-shares/68498</link>
		<comments>http://www.stockbloghub.com/2011/03/29/amln-amylin-pharmaceuticals-analyst-reports-neutral-on-shares/68498#comments</comments>
		<pubDate>Tue, 29 Mar 2011 14:41:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68498</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). The company reported a net loss of $0.94 per share in 2010, narrower than the Zacks Consensus Estimate of $1.26 and the year-ago loss of $1.20. Full year revenues came in at $668.8 million, down 11.8%. Despite a decline in revenues, Amylin posted better-than-expected results due to lower expenses. We believe the company will continue controlling costs and have reduced our 2011 loss estimate by 22 cents. Meanwhile, Amylin faced a huge setback in 2010 when it failed to gain approval for its lead pipeline candidate, Bydureon, for the second time. Amylin and its partners, Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS), were looking to get Bydureon approved for the treatment of type II diabetes. On the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/29/amln-amylin-pharmaceuticals-analyst-reports-neutral-on-shares/68498/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Releases Disappointing Data</title>
		<link>http://www.stockbloghub.com/2011/03/28/amln-amylin-pharmaceuticals-releases-disappointing-data/68116</link>
		<comments>http://www.stockbloghub.com/2011/03/28/amln-amylin-pharmaceuticals-releases-disappointing-data/68116#comments</comments>
		<pubDate>Mon, 28 Mar 2011 22:25:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68116</guid>
		<description><![CDATA[Shares of Amylin Pharmaceuticals, Inc. (AMLN) lost more than 25% when the company released disappointing data on Bydureon (exenatide once-weekly) from a head-to-head study. Bydureon failed to achieve its primary endpoint of non-inferiority in the DURATION-6 study, which compared Bydureon with Novo Nordisk’s (NVO) Victoza. Results showed that patients in the Bydureon arm achieved a reduction of 1.3 percentage points in A1C levels compared to a reduction of 1.5 percentage points in the Victoza arm. Although gastrointestinal adverse events were less frequent in the Bydureon arm, the candidate’s failure to achieve the primary endpoint is a major setback. The disappointing DURATION-6 data is the latest setback faced by Amylin and its partners, Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS), in the development of Bydureon. Earlier in October 2010, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/28/amln-amylin-pharmaceuticals-releases-disappointing-data/68116/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Amylin Pharmaceuticals Collaborates with Biocon</title>
		<link>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973</link>
		<comments>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973#comments</comments>
		<pubDate>Fri, 11 Sep 2009 23:16:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14973</guid>
		<description><![CDATA[Yesterday, Amylin Pharmaceuticals, Inc. (AMLN) entered into an exclusive agreement with Indian biotech company Biocon Limited for the development, commercialization and manufacture of a novel peptide therapeutic for the potential treatment of diabetes. This agreement should ensure the optimum utilization of the synergistic capabilities of both the companies. Both companies have a strong focus on the development of treatments for diabetes. While Amylin&#8217;s &#8220;phybrid&#8221; technology will be used for the development of the candidate, Biocon will use its know-how in recombinant microbial expression to manufacture the compound. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity. As per the terms of the agreement, development costs will be shared by the companies. Other details were not provided. The identification ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Biotech Industry &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2009/06/01/mygn-biotech-industry-zacks-analyst-interviews/7669</link>
		<comments>http://www.stockbloghub.com/2009/06/01/mygn-biotech-industry-zacks-analyst-interviews/7669#comments</comments>
		<pubDate>Mon, 01 Jun 2009 23:05:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DCGN]]></category>
		<category><![CDATA[deCODE genetics Inc.]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=7669</guid>
		<description><![CDATA[OVERVIEW The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies), while the Dow Jones Biotech Index declined 3% (which includes 33 companies). At the same time, both the NASDAQ Composite and S&#38;P 500 have achieved positive returns. NASDAQ has made a gain of 11% as of 5/26/09 and the S&#38;P 500 has gained 0.8%, while the Dow Jones Industrials reached a negative 3.5% return. This constitutes a sharp contrast with last year when the Biotech industry as a whole achieved much better performance than the market. In 2008, all three biotech ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/01/mygn-biotech-industry-zacks-analyst-interviews/7669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

